In another first, the US Food and Drug Administration has given an emergency use authorization (EUA) to Cue Health’s over-the-counter at-home molecular diagnostic test. The green light comes after massive government investment in the company last year.
On 5 March, the FDA said it has given marketing authorization to Cue Health’s at-home molecular nucleic acid amplification test (NAAT), which is capable of detecting genetic material from the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?